A multi-centre phase I trial of the PARP inhibitor olaparib in patients with relapsed chronic lymphocytic leukaemia, T-prolymphocytic leukaemia or mantle cell lymphoma.
Authors
Pratt, GYap, C
Oldreive, C
Slade, D
Bishop, R
Griffiths, M
Dyer, M
Fegan, C
Oscier, D
Pettitt, A
Matutes, E
Devereux, S
Allsup, D
Bloor, Adrian
Hillmen, P
Follows, G
Rule, S
Moss, P
Stankovic, T
Affiliation
University Hospitals Birmingham NHS Foundation Trust, BirminghamIssue Date
2017-06-23
Metadata
Show full item recordCitation
A multi-centre phase I trial of the PARP inhibitor olaparib in patients with relapsed chronic lymphocytic leukaemia, T-prolymphocytic leukaemia or mantle cell lymphoma. 2017 Br J HaematolJournal
British Journal of HaematologyDOI
10.1111/bjh.14793PubMed ID
28643365Type
ArticleLanguage
enISSN
1365-2141ae974a485f413a2113503eed53cd6c53
10.1111/bjh.14793